Modified low density lipoprotein and lipoprotein-containing circulating immune complexes as diagnostic and prognostic biomarkers of atherosclerosis and type 1 diabetes macrovascular disease

International Journal of Molecular Sciences

Volumn 15, Issue 7, 2014, Pages 12807-12841

  Orekhov, Alexander N ^a,b   Bobryshev, Yuri V ^a,c,d   Sobenin, Igor A ^a,e   Melnichenko, Alexandra A ^a   Chistiakov, Dimitry A ^f  

^a INSTITUTE OF GENERAL PATHOLOGY AND PATHOPHYSIOLOGY   (Russian Federation)

^b Institute for Atherosclerosis Research   (Russian Federation)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d UNIVERSITY OF WESTERN SYDNEY   (Australia)

^e INSTITUTE OF EXPERIMENTAL CARDIOLOGY   (Russian Federation)

^f PIROGOV RUSSIAN NATIONAL RESEARCH MEDICAL UNIVERSITY   (Russian Federation)

Author keywords

Atherogenesis; Atherosclerosis; Immune complexes; low density lipoproteins; Inflammation

Indexed keywords

ANTI LOW DENSITY LIPOPROTEIN ANTIBODY; AUTOANTIBODY; GLYCOSYLATED PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; LIPOPROTEIN; LIPOPROTEIN C; LOW DENSITY LIPOPROTEIN; LYSOPHOSPHATIDYLCHOLINE; MONOCYTE CHEMOTACTIC PROTEIN 1; REACTIVE OXYGEN METABOLITE; SPHINGOMYELIN; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VERY LOW DENSITY LIPOPROTEIN; ANTIGEN ANTIBODY COMPLEX; BIOLOGICAL MARKER;

ANTIGEN ANTIBODY COMPLEX; APOPTOSIS; ATHEROSCLEROSIS; CARBAMOYLATION; CARDIOVASCULAR DISEASE; DESILYLATION; HUMAN; IMMUNOGENICITY; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN EXPRESSION; PROTEIN MODIFICATION; REVIEW; VASCULAR SMOOTH MUSCLE; ANIMAL; BLOOD; COMPLICATION; DIABETIC ANGIOPATHIES; IMMUNOLOGY; METABOLISM;

ANIMALS; ANTIGEN-ANTIBODY COMPLEX; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; DIABETES MELLITUS, TYPE 1; DIABETIC ANGIOPATHIES; HUMANS; LIPOPROTEINS, LDL;

EID: 84904618563     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms150712807     Document Type: Review

References (220)

1. Schwartz, S.M.; deBlois, D.; O'Brien, E.R. The intima-Soil for atherosclerosis and restenosis. Circ. Res. 1995, 77, 445-465.
2. Andreeva, E.R.; Pugach, I.M.; Orekhov, A.N. Collagen-synthesizing cells ininitial and advanced atherosclerotic lesions of human aorta. Atherosclerosis 1997, 130, 133-142.
3. Ryu, C.W.; Kwak, H.S.; Jahng, G.H.; Lee, H.N. High-resolution MRI of intracranial atherosclerotic disease. Neurointervention 2014, 9, 9-20.
4. Michel, J.B.; Martin-Ventura, J.L.; Nicoletti, A.; Ho-Tin-Noé, B. Pathology of human plaque vulnerability: Mechanisms and consequences of intraplaque haemorrhages. Atherosclerosis 2014, 234, 311-319.
5. Watts, G.F.; Gidding, S.; Wierzbicki, A.S.; Toth, P.P.; Alonso, R.; Brown, W.V.; Bruckert, E.; Defesche, J.; Lin, K.K.; Livingston, M.;et al. Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation. Int. J. Cardiol. 2014, 171, 309-325.
6. Noyes, A.M.; Thompson, P.D. A systematic reviewof the time course of atherosclerotic plaque regression. Atherosclerosis 2014, 234, 75-84.
7. Afonso, L.; Veeranna, V.; Zalawadiya, S.; Ramesh, K.; Niraj, A.; Panaich S. Predictors of residual cardiovascular risk in patients on statin therapy for primary prevention. Cardiology 2011, 119, 187-190.
8. Bedi, U.S.; Singh, M.; Singh, P.P.; Bhuriya, R.; Bahekar, A.; Molnar, J.; Khosla, S.; Arora, R. Effects of statins on progression of carotid atherosclerosis as measured by carotid intimal-medial thickness: A meta-analysis of randomized controlled trials. J. Cardiovasc. Pharmacol. Ther. 2010, 15, 268-273.
9. Whayne, T.F., Jr. Problems and possible solutions for therapy with statins. Int. J. Angiol. 2013, 22, 75-82.
10. Di Angelantonio, E.; Gao, P.; Pennells, L.; Kaptoge, S.; Caslake, M.; Thompson, A.; Butterworth, A.S.; Sarwar, N.; Wormser, D.; Saleheen, D.;et al. Lipid-related markers and cardiovascular disease prediction. JAMA 2012, 307, 2499-2506.
11. Benitez, R.M.; Vogel, R.A. Assessment of subclinical atherosclerosis and cardiovascular risk. Clin. Cardiol. 2001, 24, 642-650.
12. Belcaro, G.; Nicolaides, A.N.; Ramaswami, G.; Cesarone, M.R.; de Sanctis, M.; Incandela, L.; Ferrari, P.; Geroulakos, G.; Barsotti, A.; Griffin, M.;et al. Carotid and femoral ultrasound morphology screening and cardiovascular events in low risk subjects: A 10-year follow-up study (the CAFES-CAVE study). Atherosclerosis 2001, 156, 379-387.
13. Grewal, J.; Anand, S.; Islam, S.; Lonn, E. Prevalence and predictors of subclinical atherosclerosis among asymptomatic "low risk" individuals in a multiethnic population. Atherosclerosis 2008, 197, 435-442.
14. Castellon, X.; Bogdanova, V. Screening for subclinical atherosclerosis by noninvasive methods in asymptomatic patients with risk factors. Clin. Interv. Aging 2013, 8, 573-580.
15. Bobryshev, Y.V. Novel targets and biomarkers for anti-atherosclerotic therapy. Curr. Pharm. Des. 2013, 19, 5837-5839.
16. Ross, R. Cell biology of atherosclerosis. Annu. Rev. Physiol. 1995, 57, 791-804.
17. Tertov, V.V.; Bittolo-Bon, G.; Sobenin, I.A.; Cazzolato, G.; Orekhov, A.N.; Avogaro, P. Naturally occurring modified low density lipoproteins are similar if not identical: More electronegative and desialylated lipoprotein subfractions. Exp. Mol. Pathol. 1995, 62, 166-172.
18. Pentikäinen, M.O.; Oörni, K.; Ala-Korpela, M.; Kovanen, P.T. Modified LDL-trigger of atherosclerosis and inflammation in the arterial intima. J. Intern. Med. 2000, 247, 359-370.
19. Mahley, R.W.; Innerarity, T.L.; Rall, S.C., Jr.; Weisgraber, K.H. Plasma lipoproteins: Apolipoprotein structure and function. J. Lipid Res. 1984, 25, 1277-1294.
20. Cho, N.H.; Seong, S.Y. Apolipoproteins inhibit the innate immunityactivated by necrotic cells or bacterial endotoxin. Immunology 2009, 128, e479-e586.
21. Fisher, W.R. The structure of the lower-densitylipoproteins of human plasma: Newer concepts derived from studies with the analytical ultracentrifuge. Ann. Clin. Lab. Sci. 1972, 2, 198-208.
22. Williams, P.T.; Vranizan, K.M.; Krauss, R.M. Correlations of plasma lipoproteins with LDL subfractions by particle size in men and women. J. Lipid Res. 1992, 33, 765-774.
23. Brown, M.S.; Kovanen, P.T.; Goldstein, J.L. Regulation of plasma cholesterol by lipoprotein receptors. Science 1981, 212, 628-635.
24. Hegele, R.A. Plasma lipoproteins: Genetic influences and clinical implications. Nat. Rev. Genet. 2009, 10, 109-121.
25. Hevonoja, T.; Pentikäinen, M.O.; Hyvonen, M.T.; Kovanen, P.T.; Ala-Korpela, M. Structure of low density lipoprotein (LDL) particles: Basis for understanding molecular changes in modified LDL. Biochim. Biophys. Acta 2000, 1488, 189-210.
26. Segrest, J.P.; Jones, M.K.; de Loof, H.; Dashti, N. Structure of apolipoprotein B-100 in low density lipoproteins. J. Lipid Res. 2001, 42, 1346-1367.
27. Kane, J.P. Apoprotein B: Structural and metabolic heterogeneity. Annu. Rev. Physiol. 1983, 45, 637-650.
28. Yang, C.Y.; Gu, Z.W.; Weng, S.A.; Kim, T.W.; Chen, S.H.; Pownall, H.J.; Sharp, P.M.; Liu, S.W.; Li, W.H.; Gotto, A.M., Jr. Structure ofapolipoprotein B-100 of human low density lipoproteins. Arteriosclerosis 1989, 9, 96-108.
29. Segrest, J.P.; Jones, M.K.; Mishra, V.K.; Anantharamaiah, G.M.; Garber. D.W. ApoB-100 has a pentapartite structure composed of three amphipathic alpha-helicaldomains alternating with two amphipathic beta-strand domains. Detection by the computer program LOCATE. Arterioscler. Thromb. 1994, 14, 1674-1685
30. Segrest, J.P.; Jones, M.K.; Mishra, V.K.; Pierotti, V.; Young, S.H.; Boren, J.; Innerarity, T.L.; Dashti, N. Apolipoprotein B-100: Conservation of lipid-associating amphipathic secondary structural motifs in nine species of vertebrates. J. Lipid Res. 1998,39, 85-102.
31. Powell, L.M.; Wallis, S.C.; Pease, R.J.; Edwards, Y.H.; Knott, T.J.; Scott, J. A novel form of tissue-specific RNA processing produces apolipoprotein-B48 in intestine. Cell 1987, 50, 831-840.
32. Kumar, V.; Butcher, S.J.; Öörni, K.; Engelhardt, P.; Heikkonen, J.; Kaski, K.; Ala-Korpela, M.; Kovanen, P.T. Three-dimensional cryoEM reconstruction of native LDL particles to 16Å resolution at physiological body temperature. PLoS One 2011, 6, e18841.
33. Forgez, P.; Gregory, H.; Young, J.A.; Knott, T.; Scott, J.; Chapman, M.J. Identification of surface-exposed segments of apolipoprotein B-100 in the LDL particle. Biochem. Biophys. Res. Commun. 1986, 140, 250-257.
34. Segrest, J.P.; Jones, M.K.; Dashti, N. N-terminal domain of apolipoprotein B has structural homology to lipovitellin and microsomal triglyceride transfer protein: A "lipid pocket" model for self-assembly of apob-containing lipoprotein particles. J. Lipid Res. 1999, 40, 1401-1416.
35. Schneider, W.J. The low density lipoprotein receptor. Biochim. Biophys. Acta 1989, 988, 303-317.
36. Bobryshev, Y.V. Monocyte recruitment and foam cell formation inatherosclerosis. Micron 2006, 37, 208-222.
37. Rezaee, F.; Casetta, B.; Levels, J.H.; Speijer, D.; Meijers, J.C. Proteomic analysis of high-density lipoprotein. Proteomics 2006, 6, 721-730.
38. Queiroz, K.C.; Tio, R.A.; Zeebregts, C.J.; deVries, M.; Mahmoudi, M.; Peppelenbosch, M.P.; Rezaee, F. Human plasma very low density lipoprotein carries Indian hedgehog. J. Proteome Res. 2010, 9, 6052-6059.
39. Dashty, M.; Motazacker, M.M.; Levels, J.; de Vries, M.; Mahmoudi, M.; Peppelenbosch, M.P.; Rezaee, F. Proteome of human plasma very low-density lipoprotein and low-density lipoprotein exhibits a link with coagulation and lipid metabolism. Thromb. Haemost. 2014, 111, 518-530.
40. Yuasa, Y.; Osaki, T.; Makino, H; Iwamoto, N;Kishimoto, I.; Usami, M.; Minamino, N.; Harada-Shiba, M. Proteomic analysis of proteins eliminated by low-density lipoprotein apheresis. Ther. Apher. Dial. 2014, 18, 93-102.
41. Karlsson, H.; Leanderson, P.; Tagesson, C.; Lindahl, M. Lipoproteomics I:Mapping of proteins in low-density lipoprotein using two-dimensional gel electrophoresisand mass spectrometry. Proteomics 2005, 5, 551-565.
42. Lepedda, A.J.; Nieddu, G.; Zinellu, E.; de Muro, P.; Piredda, F.; Guarino, A.; Spirito, R.; Carta, F.; Turrini, F.; Formato M. Proteomic analysis of plasma-purified VLDL, LDL, and HDL fractions from atheroscleroticpatients undergoing carotid endarterectomy: Identification of serum amyloid A as a potential marker. Oxid. Med. Cell Longev. 2013, 2013, 385214.
43. Dong, Z.; Wu, T.; Qin, W.; An, C.; Wang, Z.; Zhang, M.; Zhang, Y.; Zhang, C.; An, F. Serum amyloid a directly accelerates the progression ofatherosclerosis in apolipoprotein E-deficient mice. Mol. Med. 2011, 17, 1357-1364.
44. Song, C.; Hsu, K.; Yamen, E.; Yan, W.; Fock, J.; Witting, P.K.; Geczy, C.L.; Freedman, S.B. Serum amyloid A induction of cytokines in monocytes/macrophages and lymphocytes. Atherosclerosis 2009, 207, 374-383.
45. Prassl, R.; Laggner, P. Lipoprotein structure and dynamics: Low density lipoprotein viewed as a highly dynamic and flexible nanoparticle. InTech 2012, doi:10.5772/48145.
46. Bancells, C.; Benítez, S.; Villegas, S.; Jorba, O.; Ordóñez-Llanos, J.; Sánchez-Quesada, J.L. Novel phospholipolytic activities associated with electronegative low-density lipoprotein are involved in increased self-aggregation. Biochemistry 2008,47, 8186-8194.
47. Sweet, M.J.; Hume, D.A. Endotoxin signal transduction in macrophages. J. Leukoc. Biol. 1996, 60, 8-26.
48. Liu, Y.H.; Atkinson, D. Enhancing the contrast of ApoB to locate the surface components in the 3D density map of human LDL. J. Mol. Biol. 2011, 405, 274-283.
49. Deckelbaum, R.J.; Shipley, G.G.; Small, D.M.; Lees, R.S.; George, P.K. Thermal transitions in human plasma low density lipoproteins. Science 1975, 190, 392-394.
50. Deckelbaum, R.J.; Shipley, G.G.; Small, D.M. Structure and interactions of lipids in human plasma low density lipoproteins. J. Biol. Chem. 1977, 252, 744-754.
51. Reis, A.; Rudnitskaya, A.; Blackburn, G.J.; Mohd Fauzi, N.; Pitt, A.R.; Spickett, C.M. A comparison of five lipid extraction solvent systems for lipidomic studies of human LDL. J. Lipid Res. 2013, 54, 1812-1824.
52. Kanno, K.; Wu, M.K.; Agate, D.A.; Fanelli, B.K.; Wagle, N.; Scapa, E.F.; Ukomadu, C.; Cohen, D.E. Interacting proteins dictate function of the minimal START domain phosphatidylcholine transfer protein/StarD2. J. Biol. Chem. 2007, 282, 30728-30736.
53. Yao, Z.M.; Vance, D.E. The active synthesis ofphosphatidylcholine is required for very low density lipoprotein secretion from rat hepatocytes. J. Biol. Chem. 1988, 263, 2998-3004.
54. Slotte, J.P. Biological functions of sphingomyelins. Prog. Lipid Res. 2013, 52, 424-437.
55. Wang, Z.; Klipfell, E.; Bennett, B.J.; Koeth, R.; Levison, B.S.; Dugar, B.; Feldstein, A.E.; Britt, E.B.; Fu, X.; Chung, Y.M.;et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 2011, 472, 57-63.
56. Serrano, D.; Bhowmick, T.; Chadha, R.; Garnacho, C.; Muro, S. Intercellular adhesion molecule 1 engagement modulates sphingomyelinase and ceramide, supporting uptake of drug carriers by the vascular endothelium. Arterioscler. Thromb. Vasc. Biol. 2012, 32, 1178-1185.
57. Merrill, A.H., Jr.; Lingrell, S.; Wang, E.; Nikolova-Karakashian, M.; Vales, T.R.; Vance, D.E. Sphingolipid biosynthesis de novoby rat hepatocytes in culture. Ceramide and sphingomyelin are associated with, but not required for, very-low density lipoprotein (VLDL) secretion. J. Biol. Chem. 1995, 270, 13834-13841.
58. Nikolova-Karakashian, M.N. Ceramide in serum lipoproteins: Function and regulation of metabolism. In Ceramide Signaling; Futerman, A.H., Ed.; Kluwer Academic/Plenum: Dordrecht, The Netherlands, 2002; Available online: http://www.landesbioscience.com/pdf/ Futerman15nikolova.pdf (accessed on 26 June 2014)
59. Hannun, Y.A.; Luberto, C.; Argraves, K.M. Enzymes of sphingolipid metabolism: From modular to integrative signaling. Biochemistry 2001, 40, 4893-4903.
60. Schissel, S.L.; Keesler, G.A.; Schuchman, E.H.; Williams, K.J.; Tabas, I. The cellular trafficking and zinc dependence of secretory and lysosomal sphingomyelinase, two products of the acid sphingomyelinase gene. J. Biol. Chem. 1998, 273, 18250-18259.
61. Marathe, S.; Kuriakose, G.; Williams, K.J.; Tabas, I. Sphingomyelinase, an enzyme implicated in atherogenesis, is present in atherosclerotic lesions and binds to specific components of the subendothelial extracellular matrix. Arterioscler. Thromb. Vasc. Biol. 1999, 19, 2648-2658.
62. Marathe, S.; Choi, Y.; Leventhal, A.R.; Tabas, I. Sphingomyelinase converts lipoproteins from apolipoprotein E knockout mice into potent inducers of macrophage foam cell formation. Arterioscler. Thromb. Vasc. Biol. 2000, 20, 2607-2613.
63. Boyanovsky, B.; Karakashian, A.; King, K.; Giltiay, N.; Nikolova-Karakashian, M. Uptake and metabolism of low density lipoproteins with elevated ceramide content by human microvascular endothelial cells: Implications for the regulation of apoptosis. J. Biol. Chem. 2003, 278, 26992-26999.
64. Matsunaga, T.; Kotamraju, S.; Kalivendi, S.V.; Dhanasekaran, A.; Joseph, J.; Kalyanaraman, B. Ceramide-induced intracellular oxidant formation, iron signaling, and apoptosis in endothelial cells: Protective role of endogenous nitric oxide. J. Biol. Chem. 2004, 279, 28614-28624.
65. Spiegel, S.; Milstien, S. Sphingosine-1-phosphate: An enigmatic signalling lipid. Nat. Rev. Mol. Cell. Biol. 2003, 4, 397-407.
66. Chandru, H.; Boggaram, V. The role of sphingosine 1-phosphate in the TNF-αinduction ofIL-8 gene expression in lung epithelial cells. Gene 2007, 391, 150-160.
67. Sánchez-Quesada, J.L.; Benítez, S.; Ordóñez-Llanos, J. Electronegative low-density lipoprotein. Curr. Opin. Lipidol. 2004, 15, 329-335.
68. Benítez, S.; Camacho, M.; Arcelus, R.; Vila, L.; Bancells, C.; Ordóñez-Llanos, J.; Sánchez-Quesada, J.L. Increased lysophosphatidylcholine and non-esterified fatty acid content in LDL induces chemokine release inendothelial cells. Relationship with electronegative LDL. Atherosclerosis 2004, 177, 299-305.
69. Oörni, K.; Pentikäinen, M.O.; Ala-Korpela, M.; Kovanen, P.T. Aggregation, fusion, and vesicle formation of modified low density lipoprotein particles: Molecular mechanisms and effects on matrix interactions. J. Lipid Res. 2000, 41, 1703-1714.
70. Hajjar, D.P.; Pomerantz, K.B. Signal transduction inatherosclerosis: Integration of cytokines and the eicosanoid network. FASEB J. 1992, 6, 2933-2941.
71. Orekhov, A.N. Direct anti-atherosclerotic therapy;development of natural anti-atherosclerotic drugs preventing cellular cholesterol retention. Curr. Pharm. Des. 2013, 19, 5909-5928.
72. Kannel, W.B.; Castelli, W.P.; Gordon, T. Cholesterol in the prediction of atherosclerotic disease. New perspectives based on the Framingham study. Ann. Intern. Med. 1979, 90, 85-91.
73. Brunzell, J.D.; Davidson, M.; Furberg, C.D.; Goldberg, R.B.; Howard, B.V.; Stein, J.H.; Witztum, J.L. Lipoprotein management inpatients with cardiometabolic risk. J. Am. Coll. Cardiol. 2008, 51, 1512-1524.
74. Ramjee, V.; Sperling, L.S.; Jacobson, T.A. Non-high-density lipoprotein cholesterolversus apolipoprotein B in cardiovascular risk stratification: Do the math. J. Am. Coll. Cardiol. 2011, 58, 457-463.
75. Robinson, J.G.; Wang, S.; Jacobson, T.A. Meta-analysis of comparison of effectiveness of lowering apolipoprotein Bversuslow-density lipoprotein cholesterol and nonhigh-density lipoprotein cholesterol for cardiovascularrisk reduction in randomized trials. Am. J. Cardiol. 2012, 110, 1468-1476.
76. Milne, R.W.; Weech, P.K.; Marcel, Y.L. Heterogeneity of apolipoprotein B containing lipoproteins. Adv. Exp. Med. Biol. 1987,210, 1-5.
77. Martin, S.S.; Qasim, A.N.; Wolfe, M.; St Clair, C.; Schwartz, S.; Iqbal, N.; Schutta, M.; Bagheri, R.; Mehta, N.N.; Rader, D.J.; et al. Comparison of high-density lipoprotein cholesterol to apolipoprotein A-I and A-II to predict coronary calcium and the effect of insulin resistance. Am. J. Cardiol. 2011, 107, 393-398.
78. Grundy, S.M. Use of emerging lipoprotein risk factors in assessment of cardiovascular risk. JAMA 2012, 307, 2540-2542.
79. Itabe, H.; Obama, T.; Kato, R. The dynamics of oxidized LDL during atherogenesis. J. Lipids 2011, 2011, 418313.
80. Kim, J.A.; Territo, M.C.; Wayner, E.; Carlos, T.M.; Parhami, F.; Smith, C.W.; Haberland, M.E.; Fogelman, A.M.; Berliner, J.A. Partial characterization of leukocyte binding molecules on endothelial cells induced by minimally oxidized LDL. Arterioscler. Thromb. 1994, 14, 427-433.
81. Tanner, F.C.; Boulanger, C.M.; Lüscher, T.F. Endothelium-derived nitricoxide, endothelin, and platelet vessel wall interaction: Alterations in hypercholesterolemia and atherosclerosis. Semin. Thromb. Hemost. 1993, 19, 167-175.
82. Liao, J.K. Inhibition of Gi proteins by low density lipoprotein attenuates bradykinin-stimulated release of endothelial-derived nitric oxide. J. Biol. Chem. 1994, 269, 12987-12992.
83. Singh, R.B.; Mengi, S.A.; Xu, Y.J.; Arneja, A.S.; Dhalla, N.S. Pathogenesis of atherosclerosis: A multifactorial process. Exp. Clin. Cardiol. 2002, 7, 40-53.
84. Jaakkola, O.; Solakivi, T.; Tertov, V.V.; Orekhov, A.N.; Miettinen, T.A.; Nikkari, T. Characteristics of low-density lipoprotein subfractions from patients with coronary artery disease. Coron. Artery Dis. 1993, 4, 379-385.
85. Tertov, V.V.; Orekhov, A.N. Metabolism of native and naturally occurring multiple modified low density lipoprotein in smooth muscle cells of human aortic intima. Exp. Mol. Pathol. 1997, 64, 127-145.
86. Botham, K.M.; Moore, E.H.; de Pascale, C.; Bejta, F. The induction of macrophage foam cell formation by chylomicron remnants. Biochem. Soc. Trans. 2007, 35, 454-458.
87. Marchant, C.E.; van der Veen, C.; Law, N.S.; Hardwick, S.J.; Carpenter, K.L.; Mitchinson, M.J. Oxidation of low-density lipoprotein by human monocyte-macrophages results in toxicity to the oxidising culture. Free Radic. Res. 1996, 24, 333-342.
88. Tsimikas, S.; Miller, Y.I. Oxidative modification of lipoproteins: Mechanisms, role in inflammation and potential clinical applications in cardiovascular disease. Curr. Pharm. Des. 2011, 17, 27-37.
89. Kacharava, A.G.; Tertov, V.V.; Orekhov, A.N. Autoantibodies against low-density lipoprotein and atherogenic potential of blood. Ann. Med. 1993, 25, 551-555.
90. Gounopoulos, P.; Merki, E.; Hansen, L.F.; Choi, S.H.; Tsimikas, S. Antibodies to oxidized low density lipoprotein: Epidemiological studies and potential clinical applications in cardiovascular disease. Minerva Cardioangiol. 2007, 55, 821-837.
91. Burut, D.F.; Karim, Y.; Ferns, G.A. The role of immune complexes in atherogenesis. Angiology 2010, 61, 679-689.
92. Sobenin, I.A.; Chistiakov, D.A.; Bobryshev, Y.V.; Orekhov, A.N. Blood atherogenicity as a target for anti-atherosclerotic therapy. Curr. Pharm. Des. 2013, 19, 5954-5962.
93. Iughetti, L.; Volta, C.; Maggi, E.; Palladini, G.; Perugini, C.; Bellomo, G.; Bernasconi, S. Circulating antibodies recognizing oxidatively modified low-density lipoprotein in children. Pediatr. Res. 1999, 45, 94-99.
94. Wang, J.; Niu, D.; Meng, Y.; Han, A.; Li, K.; Zhang, C. Plasma oxidized lipoprotein(a) and its immune complexes are present in newborns and children. Clin. Chim. Acta 2009, 407, 1-5.
95. Steinberg, D.; Parthasarathy, S.; Carew, T.E.; Khoo, J.C.; Witztum, J.L. Beyond cholesterol. Modifications of low-density lipoprotein that increase itsatherogenicity. N. Engl. J. Med. 1989, 320, 915-924.
96. Yoshida, H.; Kisugi, R. Mechanisms of LDL oxidation. Clin. Chim. Acta 2010, 411, 1875-1882.
97. Delporte, C.; van Antwerpen, P.; Vanhamme, L.; Roumeguère, T.; Zouaoui Boudjeltia, K. Low-density lipoprotein modifiedby myeloperoxidase in inflammatory pathways and clinical studies. Mediat. Inflamm. 2013, 2013, 971579.
98. Delporte, C.; Boudjeltia, K.Z.; Noyon, C.; Furtmüller, P.G.; Nuyens, V.; Slomianny, M.C.; Madhoun, P.; Desmet, J.M.; Raynal, P.; Dufour, D.;et al. Impact of myeloperoxidase-LDL interactions on enzyme activity and subsequent posttranslational oxidative modifications of apoB-100. J. Lipid Res. 2014, 55, 747-757.
99. Tertov, V.V.; Kaplun, V.V.; Sobenin, I.A.; Orekhov, A.N. Low-density lipoprotein modification occurring in human plasma. Possible mechanism ofin vivolipoprotein desialylation as a primary step of atherogenic modification. Atherosclerosis 1998, 138, 183-195.
100. Ermak, N.; Lacour, B.; Drüeke, T.B.; Vicca, S. Role of reactive oxygen species and Bax in oxidized low density lipoprotein-induced apoptosis of human monocytes. Atherosclerosis 2008, 200, 247-256.
101. Sun, L.; Ishida, T.; Yasuda, T.; Kojima, Y.; Honjo, T.; Yamamoto, Y.; Yamamoto, H.; Ishibashi, S.; Hirata, K.; Hayashi, Y. RAGE mediates oxidized LDL-induced pro-inflammatory effects and atherosclerosis in non-diabetic LDL receptor-deficient mice. Cardiovasc. Res. 2009, 82, 371-381.
102. Pirillo, A.; Catapano, A.L. Soluble lectin-like oxidized low density lipoprotein receptor-1 as a biochemical marker for atherosclerosis-related diseases. Dis. Markers 2013, 35, 413-418.
103. Claise, C.; Edeas, M.; Chalas, J.; Cockx, A.; Abella, A.; Capel, L.; Lindenbaum, A. Oxidized low-density lipoprotein induces the production of interleukin-8 by endothelial cells. FEBS Lett. 1996, 398, 223-227.
104. Ryoo, S.W.; Kim, D.U.; Won, M.; Chung, K.S.; Jang, Y.J.; Oh, G.T.; Park, S.K.; Maeng, P.J.; Yoo, H.S.; Hoe, K.L. Native LDL induces interleukin-8 expression via H2O2, p38 Kinase, and activator protein-1 in human aortic smooth muscle cells. Cardiovasc. Res. 2004, 62, 185-193.
105. Wallenfeldt, K.; Fagerberg, B.; Wikstrand, J.; Hulthe, J. Oxidized low-density lipoprotein in plasma is a prognostic marker of subclinical atherosclerosis development in clinically healthy men. J. Intern. Med. 2004, 256, 413-420.
106. Chen, H.W.; Kuo, C.L.; Huang, C.S.; Kuo, S.J.; Liu, C.S. Oxidized low-density lipoproteins, autoantibodies against oxidized low-density lipoproteins and carotid intima media thickness in a clinically healthy population. Cardiology 2008, 110, 252-259.
107. Lobbes, M.B.; Lutgens, E.; Heeneman, S.; Cleutjens, K.B.; Kooi, M.E.; van Engelshoven, J.M.; Daemen, M.J.; Nelemans, P.J. Is there morethan C-reactive protein and fibrinogen? The prognostic value of soluble CD40 ligand, interleukin-6 and oxidized low-density lipoprotein with respect to coronary and cerebral vascular disease. Atherosclerosis 2006, 187, 18-25.
108. Ehara, S.; Ueda, M.; Naruko, T.; Haze, K.; Itoh, A.; Otsuka, M.; Komatsu, R.; Matsuo, T.; Itabe, H.; Takano, T.;et al. Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes. Circulation 2001, 103, 1955-1960.
109. Suzuki, T.; Kohno, H.; Hasegawa, A.; Toshima, S.; Amaki, T.; Kurabayashi, M.; Nagai, R. Diagnostic implications of circulating oxidized low density lipoprotein levels as a biochemical risk marker of coronary artery disease. Clin. Biochem. 2002, 35, 347-353.
110. Fraley, A.E.; Tsimikas, S. Clinical applicationsof circulating oxidized low-density lipoprotein biomarkers in cardiovascular disease. Curr. Opin. Lipidol. 2006, 17, 502-509.
111. Fraley, A.E.; Schwartz, G.G.; Olsson, A.G.; Kinlay, S.; Szarek, M.; Rifai, N.; Libby, P.; Ganz, P.; Witztum, J.L.; Tsimikas, S. Relationship of oxidized phospholipids and biomarkers of oxidized low-density lipoprotein withcardiovascular risk factors, inflammatory biomarkers, and effect of statin therapy in patients with acute coronary syndromes: Results from the MIRACL (Myocardial Ischemia Reduction With AggressiveCholesterol Lowering) trial. J. Am. Coll. Cardiol. 2009, 53, 2186-2196.
112. Pryor, W.A.; Stanley, J.P. Letter: A suggested mechanism for the production of malondialdehyde during the autoxidation ofpolyunsaturated fatty acids. Nonenzymatic production of prostaglandin endoperoxides during autoxidation. J. Org. Chem. 1975, 40, 3615-3617.
113. Del Rio, D.; Stewart, A.J.; Pellegrini, N. A review of recent studies on malondialdehyde as toxic molecule and biological marker of oxidative stress. Nutr. Metab. Cardiovasc. Dis. 2005, 15, 316-328.
114. Haberland, M.E.; Fogelman, A.M.; Edwards, P.A. Specificity of receptor-mediated recognition of malondialdehyde-modified low density lipoproteins. Proc. Natl. Acad. Sci. USA 1982, 79, 1712-1716.
115. Kreuzer, J.; White, A.L.; Knott, T.J.; Jien, M.L.; Mehrabian, M.; Scott, J.; Young, S.G.; Haberland, M.E. Amino terminus of apolipoprotein B suffices to produce recognition of malondialdehyde-modified low density lipoprotein by the scavenger receptor of human monocyte-macrophages. J. Lipid Res. 1997, 38, 324-342.
116. Tanaga, K.; Bujo, H.; Inoue, M.; Mikami, K.; Kotani, K.; Takahashi, K.; Kanno, T.; Saito, Y. Increased circulating malondialdehyde-modified LDL levels in patients with coronary artery diseases and their association with peak sizes of LDL particles. Arterioscler. Thromb. Vasc. Biol. 2002, 22, 662-666.
117. Miyazaki, T.; Shimada, K.; Sato, O.; Kotani, K.; Kume, A.; Sumiyoshi, K.; Sato, Y.; Ohmura, H.; Watanabe, Y.; Mokuno, H.;et al. Circulating malondialdehyde-modified LDL and atherogenic lipoprotein profiles measured by nuclear magneticresonance spectroscopy in patients with coronary artery disease. Atherosclerosis 2005, 179, 139-145.
118. Carmena, R.; Duriez, P.; Fruchart, J.-C. Atherosclerosis: Evolving vascularbiology and clinical implications-Atherogenic lipoprotein particles in atherosclerosis. Circulation 2004, 109, 2-7.
119. Takahashi, R.; Imamura, A.; Yoshikane, M.; Suzuki, M.; Cheng, X.W.; Numaguchi, Y.; Ikeda, N.; Murohara, T.; Okumura, K. Circulating malondialdehyde-modified low-density lipoprotein is strongly associated with very small low-density lipoprotein cholesterol concentrations in healthy men. Clin. Chim. Acta 2009, 399, 74-78.
120. Sánchez-Quesada, J.L.; Pèrez, A. Modified lipoproteins as biomarkers ofcardiovascular risk in diabetes mellitus. Endocrinol. Nutr. 2013, 60, 518-528.
121. Cohen, M.P.; Lautenslager, G.; Shea, E. Glycated LDL concentrations in non-diabetic and diabetic subjects measured with monoclonal antibodies reactive with glycated apolipoprotein B epitopes. Eur. J. Clin. Chem. Clin. Biochem. 1993, 31, 707-713.
122. Younis, N.N.; Soran, H.; Pemberton, P.; Charlton-Menys, V.; Elseweidy, M.M.; Durrington, P.N. Small dense LDL is more susceptible to glycation than more buoyant LDL in type 2 diabetes. Clin. Sci. 2013, 124, 343-349.
123. Sobenin, I.A.; Tertov, V.V.; Orekhov, A.N. Characterization of chemical composition of native and modified low density lipoprotein occurring in the blood of diabetic patients. Int. Angiol. 1994, 13, 78-83.
124. Sobenin, I.A.; Tertov, V.V.; Orekhov, A.N. Atherogenic modified LDL in diabetes. Diabetes 1996, 45, S35-S39.
125. Sobenin, I.A.; Tertov, V.V.; Koschinsky, T.; Bünting, C.E.; Slavina, E.S.; Dedov, I.I.; Orekhov, A.N. Modified low density lipoprotein from diabetic patientscauses cholesterol accumulation in human intimal aortic cells. Atherosclerosis 1993, 100, 41-54.
126. Sobenin, I.A.; Tertov, V.V.; Orekhov, A.N.; Smirnov, V.N. Synergetic effect of desialylated and glycated low density lipoproteins on cholesterol accumulation in cultured smooth muscle intimal cells. Atherosclerosis 1991, 89, 151-154.
127. Younis, N.; Sharma, R.; Soran, H.; Charlton-Menys, V.; Elseweidy, M.; Durrington, P.N. Glycation as an atherogenic modification of LDL. Curr. Opin. Lipidol. 2008, 19, 378-384.
128. Del Turco, S.; Basta, G. An update on advanced glycation endproducts and atherosclerosis. Biofactors 2012, 38, 266-274.
129. De Michele, G.; Correale, M.; de Michele, O.; Guerra, V.; Mazzarelli, R.; Misciagna, G. Evaluation of serum biomarkers in nutritional disorders: Glycated apolipoprotein B, fasting serum glucose, fructosamine, stable and labile glycated hemoglobin in diabetic and non-diabetic subjects. Immunopharmacol. Immunotoxicol. 2008, 30, 925-936.
130. Misciagna, G.; Logroscino, G.; deMichele, G.; Guerra, V.; Cisternino, A.M.; Caruso, M.G.; Trevisan, M. Glycated apolipoprotein B and myocardial infarction. Nutr. Metab. Cardiovasc. Dis. 2007, 17, 6-12.
131. Hayashi, Y.; Okumura, K.; Matsui, H.; Imamura, A.; Miura, M.; Takahashi, R.; Murakami, R.; Ogawa, Y.; Numaguchi, Y.; Murohara, T. Impact of low-density lipoprotein particle size on carotid intima-media thickness in patients with type 2 diabetes mellitus. Metabolism 2007, 56, 608-613.
132. Liu, M.L.; Ylitalo, K.; Nuotio, I.; Salonen, R.; Salonen, J.T.; Taskinen, M.R. Association between carotid intima-media thickness and low-density lipoprotein size and susceptibility of low-density lipoprotein tooxidation in asymptomatic members offamilial combined hyperlipidemia families. Stroke 2002, 33, 1255-1260.
133. Inukai, T.; Yamamoto, R.; Suetsugu, M.; Matsumoto, S.; Wakabayashi, S.; Inukai, Y.; Matsutomo, R.; Takebayashi, K.; Aso, Y. Small low-density lipoprotein and small low-density lipoprotein/total low-density lipoprotein are closely associated with intima-media thickness of the carotid artery in Type 2 diabetic patients. J. Diabetes Complicat. 2005, 19, 269-275.
134. Basnakian, A.G.; Shah, S.V.; Ok, E.; Altunel, E.; Apostolov, E.O. Carbamylated LDL. Adv. Clin. Chem. 2010, 51, 25-52.
135. Wang, Z.; Nicholls, S.J.; Rodriguez, E.R.; Kummu, O.; Hörkkö, S.; Barnard, J.; Reynolds, W.F.; Topol, E.J.; DiDonato, J.A.; Hazen, S.L. Protein carbamylation links inflammation, smoking, uremia and atherogenesis. Nat. Med. 2007,13, 1176-1184.
136. Shiu, S.W.; Xiao, S.M.; Wong, Y.; Chow, W.S.; Lam, K.S.; Tan, K.C. Carbamylation of LDL and its relationship with myeloperoxidase in type 2 diabetes mellitus. Clin. Sci. 2014, 126, 175-181.
137. Gonen, B.; Cole, T.; Hahm, K.S. The interaction of carbamylated low-density lipoprotein with cultured cells-Studies with human fibroblasts, rat peritoneal macrophages and human monocyte-derived macrophages. Biochim. Biophys. Acta 1983, 754, 201-207.
138. Roxborough, H.E.; Young, I.S. Carbamylation of proteins and atherogenesis in renal failure. Med. Hypotheses 1995, 45, 125-128.
139. Kumar, J.; Shah, S.V. Kidney disease as an independent risk factor for cardiovascular events. J. Ren. Nutr. 2005, 15, 99-104.
140. Hörkkö, S.; Huttunen, K.; Kervinen, K.; Kesāniemi, Y.A. Decreased clearance of uraemic and mildly carbamylated low-density lipoprotein. Eur. J. Clin. Investig. 1994, 24, 105-113.
141. Ok, E.; Basnakian, A.G.; Apostolov, E.O.; Barri, Y.M.; Shah, S.V. Carbamylated low-density lipoprotein induces death of endothelial cells: A link to atherosclerosis in patients with kidney disease. Kidney Int. 2005, 68, 173-178.
142. Apostolov, E.O.; Ok, E.; Burns, S.; Nawaz, S.; Savenka, A.; Shah, S.; Basnakian, A.G. Carbamylated-oxidized LDL: Proatherosclerotic effects on endothelial cells and macrophages. J. Atheroscler. Thromb. 2013, 20, 878-892.
143. Speer, T.; Owala, F.O.; Holy, E.W.; Zewinger, S.; Frenzel, F.L.; Stähli, B.E.; Razavi, M.; Triem, S.; Cvija, H.; Rohrer, L.;et al. Carbamylated low-density lipoprotein induces endothelial dysfunction. Eur. Heart J. 2014, doi:10.1093/eurheartj/ehu111.
144. Asci, G.; Basci, A.; Shah, S.V.; Basnakian, A.; Toz, H.; Ozkahya, M.; Duman, S.; Ok, E. Carbamylated low-density lipoprotein induces proliferation and increases adhesion molecule expression of human coronary artery smooth muscle cells. Nephrology 2008, 13, 480-486.
145. Apostolov, E.O.; Shah, S.V.; Ok, E.; Basnakian, A.G. Carbamylated low-density lipoprotein induces monocyte adhesion to endothelial cells throughintercellular adhesion molecule-1 and vascular cell adhesion molecule-1. Arterioscler. Thromb. Vasc. Biol. 2007, 27, 826-832.
146. Carracedo, J.; Merino, A.; Briceno, C.; Soriano, S.; Buendía, P.; Calleros, L.; Rodriguez, M.; Martín-Malo, A.; Aljama, P.; Ramírez, R. Carbamylated low-density lipoprotein induces oxidative stress and accelerated senescence in human endothelial progenitor cells. FASEB J. 2011, 25, 1314-1322.
147. - mice and bind plasma autoantibodies in humans under enhanced carbamylation. Antioxid. Redox Signal. 2013, 19, 1047-1062.
148. Kummu, O.; Turunen, S.P.; Prus, P.; Lehtimäki, J.; Veneskoski, M.; Wang, C.; Hörkkö, S. Human monoclonal Fab and human plasma antibodies to carbamyl-epitopes cross-react with malondialdehyde-adducts. Immunology 2014, 141, 416-430.
149. Tertov, V.V.; Orekhov, A.N.; Sobenin, I.A.; Morrisett, J.D.; Gotto, A.M., Jr.; Guevara, J.G., Jr. Carbohydrate composition of protein and lipid components in sialic acid-rich and-poor low density lipoproteins from subjects withand without coronary artery disease. J. Lipid Res. 1993, 34, 365-375.
150. Attie, A.D.; Weinstein, D.B.; Freeze, H.H.; Pittman, R.C.; Steinberg, D. Unaltered catabolism of desialylated low-density lipoprotein in the pig and in cultured rat hepatocytes. Biochem. J. 1979, 180, 647-654.
151. Bartlett, A.L.; Stanley, K.K. All low density lipoprotein particles are partially desialylated in plasma. Atherosclerosis 1998, 138, 237-245.
152. Orekhov, A.N.; Tertov, V.V.; Mukhin, D.N. Desialylated low density lipoprotein-naturally occurring modified lipoproteinwith atherogenic potency. Atherosclerosis 1991, 86, 153-161.
153. Tertov, V.V.; Sobenin, I.A.; Orekhov, A.N. Modified (desialylated) low-density lipoprotein measured in serum by lectin-sorbent assay. Clin. Chem. 1995, 41, 1018-1021.
154. Tertov, V.V.; Sobenin, I.A.; Orekhov, A.N. Characterization of desialylated low-density lipoproteins which cause intracellular lipid accumulation. Int. J. Tissue React. 1992, 14, 155-162.
155. Tertov, V.V.; Orekhov, A.N.; Kacharava, A.G.; Sobenin, I.A.; Perova, N.V.; Smirnov, V.N. Low density lipoprotein-containing circulating immune complexes and coronary atherosclerosis. Exp. Mol. Pathol. 1990, 52, 300-308.
156. Grewal, T.; Bartlett, A.; Burgess, J.W.; Packer, N.H.; Stanley, K.K. Desialylated LDL uptake in human and mouse macrophages can be mediated by a lectin receptor. Atherosclerosis 1996, 121, 151-163.
157. Orekhov, A.N.; Tertov, V.V.; Mukhin, D.N.; Mikhailenko, I.A. Modification of low density lipoprotein by desialylation causes lipid accumulation in cultured cells: Discovery of desialylated lipoprotein with altered cellular metabolism in the blood of atherosclerotic patients. Biochem. Biophys. Res. Commun. 1989, 162, 206-211.
158. Ruelland, A.; Gallou, G.; Legras, B.; Paillard, F.; Cloarec, L. LDL sialic acid content in patients with coronary artery disease. Clin. Chim. Acta 1993, 221, 127-133.
159. Garner, B.; Harvey, D.J.; Royle, L.; Frischmann, M.; Nigon, F.; Chapman, M.J.; Rudd, P.M. Characterization of human apolipoprotein B100 oligosaccharides in LDL subfractions derived from normal and hyperlipidemic plasma: Deficiency of α-N-acetylneuraminyllactosyl-ceramide in light and small dense LDL particles. Glycobiology 2001, 11, 791-802.
160. Dousset, N.; Dousset, J.C.; Taus, M.; Ferretti, G.; Curatola, G.; Soléra, M.L.; Valdiguié, P. Effect of desialylation on low density lipoproteins: Comparative study before and after oxidative stress. Biochem. Mol. Biol. Int. 1994, 32, 555-563.
161. Tertov, V.V.; Sobenin, I.A.; Kaplun, V.V.; Orekhov, A.N. Antioxidant content in low density lipoprotein and lipoprotein oxidationin vivoandin vitro. Free Radic. Res. 1998, 29, 165-173.
162. Tertov, V.V.; Kaplun, V.V.; Sobenin, I.A.; Boytsova, E.Y.; Bovin, N.V.; Orekhov, A.N. Human plasma trans-sialidase causes atherogenic modification of low density lipoprotein. Atherosclerosis 2001, 159, 103-115.
163. Tanaka, K.; Tokumaru, S.; Kojo, S. Possible involvement of radical reactions in desialylation of LDL. FEBS Lett. 1997, 413, 202-204.
164. Harada, L.M.; Carvalho, M.D.; Passarelli, M.; Quintão, E.C. Lipoprotein desialylation simultaneously enhances the cell cholesterol uptakeand impairs the reverse cholesterol transport system: In vitroevidences utilizing neuraminidase-treated lipoproteins and mouse peritoneal macrophages. Atherosclerosis 1998, 139, 65-75.
165. Bartlett, A.L.; Grewal, T.; de Angelis, E.; Myers, S.; Stanley, K.K. Role of the macrophage galactose lectin in the uptake of desialylated LDL. Atherosclerosis 2000, 153, 219-230.
166. Orekhov, A.N.; Tertov, V.V.; Kabakov, A.E.; Adamova, I. Yu.; Pokrovsky, S.N.; Smirnov, V.N. Autoantibodies against modified low density lipoprotein-Nonlipid factor of blood plasma that stimulates foam cell formation. Arterioscler. Thromb. 1991, 11, 316-326.
167. Tertov, V.V.; Sobenin, I.A.; Gabbasov, Z.A.; Popov, E.G.; Jaakkola, O.; Solakivi, T.; Nikkari, T.; Smirnov, V.N.; Orekhov, A.N. Multiple-modified desialylated low densitylipoproteins that cause intracellular lipid accumulation. Isolation, fractionation and characterization. Lab. Investig. 1992, 67, 665-675.
168. Tertov, V.V.; Sobenin, I.A.; Orekhov, A.N.; Jaakkola, O.; Solakivi, T.; Nikkari, T. Characteristics of low density lipoprotein isolated from circulating immune complexes. Atherosclerosis 1996, 122, 191-199.
169. Avogaro, P.; Bittolo-Bon, G.; Cazzolato, G. Presence of a modified low density lipoprotein in humans. Arteriosclerosis 1988, 8, 79-87.
170. Krauss, R.M. Lipoprotein subfractionsand cardiovascular disease risk. Curr. Opin. Lipidol. 2010, 21, 305-311.
171. La Belle, M.; Krauss, R.M. Differences in carbohydrate content of low density lipoproteins associated with low density lipoprotein subclass patterns. J. Lipid Res. 1990, 31, 1577-1588.
172. Lopes-Virella, F.M.; Virella, G. Pathogenic role of modified LDL antibodies and immune complexes in atherosclerosis. J. Atherosler. Thromb. 2013, 20, 743-754.
173. Mironova, M.; Virella, G.; Lopes-Virella, M.F. Isolation and characterization of human antioxidized LDL autoantibodies. Arterioscler. Thromb. Vasc. Biol. 1996, 16, 222-229.
174. Faria-Neto, J.R.; Chyu, K.Y.; Li, X.; Dimayuga, P.C.; Ferreira, C.; Yano, J.; Cercek, B.; Shah, P.K. Passive immunization with monoclonal IgM antibodies against phosphorylcholine reduces accelerated vein graft atherosclerosis in apolipoprotein E-null mice. Atherosclerosis 2006, 189, 83-90.
175. Virella, G.; Thorpe, S.R.; Alderson, N.L.; Derrick, M.B.; Chassereau, C.; Rhett, J.M.; Lopes-Virella, M.F. Definition of the immunogenic forms of modified human LDL recognized by human autoantibodies and by rabbit hyperimmune antibodies. J. Lipid Res. 2004, 45, 1859-1867.
176. Virella, G.; Lopes-Virella, M.F. Lipoprotein autoantibodies: Measurement and significance. Clin. Diagn. Lab. Immunol. 2003, 10, 499-505.
177. Palinski, W.; Rosenfeld, M.E.; Ylä-Herttuala, S.; Gurtner, G.C.; Socher, S.S.; Butler, S.W.; Parthasarathy, S.; Carew, T.E.; Steinberg, D.; Witztum, J.L. Low density lipoprotein undergoes oxidative modificationin vivo. Proc. Natl. Acad. Sci. USA 1989, 86, 1372-137.
178. Sobenin, I.A.; Jukka, T.; Salonen, J.T.; Zhelankin, A.V.; Alexandra, A.; Melnichenko, A.A.; Kaikkonen, J.; Bobryshev, Y.V.; Orekhov, A.N. Low density lipoprotein-containing circulating immune complexes: Role in atherosclerosis and diagnostic value. BioMed Res. Int. 2014, 2014, 205697.
179. Doo, Y.C.; Han, S.J.; Lee, J.H.; Cho, G.Y.; Hong, K.S.; Han, K.R.; Lee, N.H.; Oh, D.J.; Ryu, K.H.; Rhim, C.Y.;et al. Associations among oxidized low-density lipoprotein antibody, C-reactive protein, interleukin-6, and circulating cell adhesion molecules in patients with unstable angina pectoris. Am. J. Cardiol. 2004, 93, 554-558.
180. Papathanasiou, A.I.; Lourida, E.S.; Tsironis, L.D.; Goudevenos, J.A.; Tselepis, A.D. Short-and long-term elevation of autoantibody titers against oxidized LDL in patients with acute coronary syndromes-Role of the lipoprotein-associated phospholipase A2 and the effect of atorvastatin treatment. Atherosclerosis 2008, 196, 289-297.
181. Laczik, R.; Szodoray, P.; Veres, K.; Szomák, E.; Csipo, I.; Sipka, S., Jr.; Shoenfeld, Y.; Szekanecz, Z.; Soltész, P. Assessment of IgG antibodies to oxidized LDL in patients with acute coronary syndrome. Lupus 2011, 20, 730-735.
182. Ravandi, A.; Boekholdt, S.M.; Mallat, Z.; Talmud, P.J.; Kastelein, J.J.; Wareham, N.J.; Miller, E.R.; Benessiano, J.; Tedgui, A.; Witztum, J.L.;et al. Relationship of IgG and IgM autoantibodies and immune complexes to oxidized LDL with markers of oxidation and inflammation and cardiovascular events: Results from the EPIC-Norfolk Study. J. Lipid Res. 2011, 52, 1829-1836.
183. Karvonen, J.; Pāivänsalo, M.; Kesäniemi, Y.A.; Hörkkö, S. Immunoglobulin M type of autoantibodies to oxidized low-density lipoprotein has an inverse relation to carotid artery atherosclerosis. Circulation 2003, 108, 2107-2112.
184. De Geest, B.; Collen, D. Antibodies against oxidized LDL for non-invasive diagnosis of atherosclerotic vascular disease. Eur. Heart J. 2001, 22, 1517-1518.
185. Seccia, M.; Albano, E.; Maggi, E.; Bellomo, G. Circulating autoantibodies recognizing peroxidase-oxidized low density lipoprotein. Evidence for new antigenic epitopes formedin vivo independently from lipid peroxidation. Arterioscler. Thromb. Vasc. Biol. 1997, 17, 134-140.
186. Shaw, P.X.; Hörkkö, S.; Chang, M.K.; Curtiss, L.K.; Palinski, W.; Silverman, G.J.; Witztum, J.L. Natural antibodies with the T15 idiotype may act in atherosclerosis, apoptotic clearance, and protective immunity. J. Clin. Investig. 2000, 105, 1731-1740.
187. Chou, M.Y.; Fogelstrand, L.; Hartvigsen, K.; Hansen, L.F.; Woelkers, D.; Shaw, P.X.; Choi, J.; Perkmann, T.; Bäckhed, F.; Miller, Y.I.;et al. Oxidation-specific epitopes are dominant targets of innate natural antibodies in mice and humans. J. Clin. Investig. 2009, 119, 1335-1349.
188. Orchard, T.J.; Virella, G.; Forrest, K.Y.; Evans, R.W.; Becker, D.J.; Lopes-Virella, M.F. Antibodies to oxidized LDL predict coronary artery disease in type 1 diabetes: A nested case-control study from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes 1999, 48, 1454-1458.
189. Lopes-Virella, M.F.; Virella, G.; Orchard, T.J.; Koskinen, S.; Evans, R.W.; Becker, D.J.; Forrest, K.Y. Antibodies to oxidized LDL and LDL-containing immune complexes as risk factors for coronary artery disease in diabetes mellitus. Clin. Immunol. 1999, 90, 165-172.
190. Bertoia, M.L.; Pai, J.K.; Lee, J.H.; Taleb, A.; Joosten, M.M.; Mittleman, M.A.; Yang, X.; Witztum, J.L.; Rimm, E.B.; Tsimikas, S.; et al. Oxidation-specific biomarkers and risk of peripheral artery disease.J. Am. Coll. Cardiol. 2013,61, 2169-2179.
191. Klimov, A.N.; Denisenko, A.D.; Popov, A.V.; Nagornev, V.A.; Pleskov, V.M.; Vinogradov, A.G.; Denisenko, T.V.; Magracheva, E. Ya.; Kheifes, G.M.; Kuznetzov, A.S. Lipoprotein-antibody immune complexes. Their catabolism and role in foam cell formation. Atherosclerosis 1985, 58, 1-15.
192. Klimov, A.N.; Denisenko, A.D.; Vinogradov, A.G.; Nagornev, V.A.; Pivovarova, Y.I.; Sitnikova, O.D.; Pleskov, V.M. Accumulation of cholesteryl esters inmacrophages incubated with human lipoprotein-antibody autoimmune complex. Atherosclerosis 1988, 74, 41-46.
193. Griffith, R.L.; Virella, G.T.; Stevenson, H.C.; Lopes-Virella, M.F. Low density lipoprotein metabolism by human macrophages activated with low density lipoprotein immune complexes-A possible mechanism of foam cell formation. J. Exp. Med. 1988, 168, 1041-1059.
194. Lopes-Virella, M.F.; Griffith, R.L.; Shunk, K.A.; Virella, G.T. Enhanced uptake and impaired intracellular metabolism of low density lipoprotein complexed with anti-low density lipoprotein antibodies. Arterioscler. Thromb. 1991, 11, 1356-1367.
195. Morganelli, P.M.; Kitzmiller, T.J.; Hemmer, R.; Fanger, M.W. Redirected targeting of LDL to human monocyte Fcγreceptors with bispecific antibodies. Arterioscler. Thromb. 1992, 12, 1131-1138.
196. Lopes-Virella, M.F.; Binzafar, N.; Rackley, S.; Takei, A.; La Via, M.; Virella, G. The uptake of LDL-IC by human macrophages: Predominant involvement of the FcγRI receptor. Atherosclerosis 1997, 135, 161-170.
197. Huang, Y.; Jaffa, A.; Koskinen, S.; Takei, A.; Lopes-Virella, M.F. Oxidized LDL-containing immune complexes induce Fcγreceptor I-mediated mitogen-activated protein kinase activation in THP-1 macrophages. Arterioscler. Thromb. Vasc. Biol. 1999, 19, 1600-1607.
198. Kiener, P.A.; Rankin, B.M.; Davis, P.M.; Yocum, S.A.; Warr, G.A.; Grove, R.I. Immune complexes of LDL induce atherogenic responses in human monocytic cells. Arterioscler. Thromb. Vasc. Biol. 1995, 15, 990-999.
199. Nagarajan, S. Anti-oxLDL IgG blocks oxLDLinteraction with CD36, but promotes FcγR, CD32A-dependent inflammatory cell adhesion. Immunol. Lett. 2007, 108, 52-61.
200. Lappalainen, J.; Lindstedt, K.A.; Oksjoki, R.; Kovanen, P.T. OxLDL-IgG immune complexes induce expression and secretion of proatherogenic cytokines by cultured human mast cells. Atherosclerosis 2011, 214, 357-363.
201. Virella, G.; Atchley, D.; Koskinen, S.; Zheng, D.; Lopes-Virella, M.F. Proatherogenic and proinflammatory properties of immune complexes prepared with purified human oxLDL antibodies and human oxLDL. Clin. Immunol. 2002, 105, 81-92.
202. Saad, A.F.; Virella, G.; Chassereau, C.; Boackle, R.J.; Lopes-Virella, M.F. OxLDL immune complexes activate complement and induce cytokine production by MonoMac 6 cells and human macrophages. J. Lipid Res. 2006, 47, 1975-1983.
203. Truman, J.P.; Al Gadban, M.M.; Smith, K.J.; Jenkins, R.W.; Mayroo, N.; Virella, G.; Lopes-Virella, M.F.; Bielawska, A.; Hannun, Y.A.; Hammad, S.M. Differential regulation of acid sphingomyelinase in macrophages stimulatedwith oxidized low-density lipoprotein (LDL) and oxidized LDL immune complexes: Rolein phagocytosis and cytokine release. Immunology 2012, 136, 30-45.
204. Hammad, S.M.; Twal, W.O.; Barth, J.L.; Smith, K.J.; Saad, A.F.; Virella, G.; Argraves, W.S.; Lopes-Virella, M.F. Oxidized LDL immune complexes and oxidized LDL differentially affect the expression of genes involved with inflammation and survival in human U937 monocytic cells. Atherosclerosis 2009, 202, 394-404.
205. Virella, G.; Lopes-Virella, M.F. Atherogenesis and the humoralimmune response to modified lipoproteins. Atherosclerosis 2008, 200, 239-246.
206. Orekhov, A.N.; Kalenich, O.S.; Tertov, V.V.; Novikov, I.D.; Vorob'eva, E.G. Cholesterol levels in circulating immune complexes as a marker of coronary atherosclerosis. In Hypercholesterolemia, Hypocholesterolemia, Hypertriglyceridemia; Marmendier, C.L., Ed; Plenum Press: New York, NY, USA, 1990; pp. 393-397.
207. Tertov, V.V.; Sobenin, I.A.; Tonevitsky, A.G.; Orekhov, A.N.; Smirnov, V.N. Isolation of atherogenic modified (desialylated) low density lipoprotein from blood of atherosclerotic patients: Separation from native lipoprotein by affinity chromatography. Biochem. Biophys. Res. Commun. 1990, 167, 1122-1127.
208. Lecomte, E.; Herbeth, B.; Clerc, G.; Khalife, K.; Siest, G.; Artur, Y. Cholesterol content of circulating immune complexes in patients with coronary stenosis and subjects without evidence of atherosclerosis. Clin. Chem. 1995, 41, 1526-1531.
209. Mironova, M.; Virella, G.; Virella-Lowell, I.; Lopes-Virella, M.F. Anti-modified LDL antibodies and LDL-containing immune complexes in IDDM patients and healthy controls. Clin. Immunol. Immunopathol. 1997, 85, 73-82.
210. Lopes-Virella, M.F.; McHenry, M.B.; Lipsitz, S.; Yim, E.; Wilson, P.F.; Lackland, D.T.; Lyons, T.; Jenkins, A.J.; Virella, G. Immune complexes containing modified lipoproteins are related to the progression of internal carotid intima-media thickness in patients with type 1 diabetes. Atherosclerosis 2007, 190, 359-369.
211. Sobenin, I.A.; Orekhova, V.A.; Melnichenko, A.A.; Bobryshev, Y.V.; Orekhov, A.N. Low density lipoprotein-containing circulating immune complexes have better prognostic value in carotid intima-media thickness progression than other lipid parameters. Int. J. Cardiol. 2013, 166, 747-748.
212. Sobenin, I.A.; Karagodin, V.P.; Melnichenko, A.A.; Bobryshev, Y.V.; Orekhov, A.N. Diagnostic and prognostic value of low density lipoprotein-containing circulating immune complexes in atherosclerosis. J. Clin. Immunol. 2013, 33, 489-495.
213. Lopes-Virella, M.F.; Hunt, K.J.; Baker, N.L.; Lachin, J.; Nathan, D.M.; Virella, G. Levels of oxidized LDL and advanced glycation end products-modified LDL in circulating immune complexes are strongly associated with increased levels of carotid intima-media thickness and its progression in type 1 diabetes. Diabetes 2011, 60, 582-589.
214. Hunt, K.J.; Baker, N.; Cleary, P.; Backlund, J.Y.; Lyons, T.; Jenkins, A.; Virella, G.; Lopes-Virella, M.F. Oxidized LDL and AGE-LDLin circulating immune complexes strongly predict progression of carotid artery IMT in type 1 diabetes. Atherosclerosis 2013, 231, 315-322.
215. Lopes-Virella, M.F.; Baker, N.L.; Hunt, K.J.; Lachin, J.; Nathan, D.; Virella, G. Oxidized LDL immune complexes and coronary arterycalcification in type 1 diabetes. Atherosclerosis 2011, 214, 462-467.
216. Lopes-Virella, M.F.; Hunt, K.J.; Baker, N.L.; Virella, G.; Moritz, T. The levels of MDA-LDL in circulating immune complexes predict myocardial infarction in the VADT study. Atherosclerosis 2012, 224, 526-531.
217. Holvoet, P.; Collen, D.; van de Werf, F. Malondialdehyde-modified LDL as a marker of acute coronary syndromes. JAMA 1999, 281, 1718-1721.
218. Yang, T.C.; Chen, Y.J.; Chang, S.F.; Chen, C.H.; Chang, P.Y.; Lu, S.C. Malondialdehyde mediates oxidized LDL-induced coronary toxicity through the Akt-FGF2 pathway via DNA methylation. J. Biomed. Sci. 2014, 21, 11.
219. Lyons, T.J.; Jenkins, A.J.; Zheng, D.; Klein, R.L.; Otvos, J.D.; Yu, Y.; Lackland, D.T.; McGee, D.; McHenry, M.B.; Lopes-Virella, M.F.;et al. Nuclear magnetic resonance-determined lipoprotein subclass profile in the DCCT/EDIC cohort: Associations with carotid intima-media thickness. Diabet. Med. 2006, 23, 955-966.
220. Klein, R.L.; Carter, R.E.; Jenkins, A.J.; Lyons, T.J.; Baker, N.L.; Gilbert, G.E.; Virella, G.; Lopes-Virella, M.F. LDL-containing immune complexes in the DCCT/EDIC cohort: Associations with lipoprotein subclasses. J. Diabetes Complicat. 2011, 25, 73-82.